CD8A and neoplasm: Furthermore, the development of checkpoint inhibitors that target and effectively block the PD-1 and CTLA-4 axes have convincingly underscored the importance of endogenous CD8+ T cells in the recognition and elimination of tumor cells, but most importantly that the cancer-specific immune response can be manipulated for therapeutic benefit.